Literature DB >> 3215938

Gas chromatographic-mass spectrometric assay for busulfan in biological fluids using a deuterated internal standard.

G Vassal1, M Re, A Gouyette.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3215938     DOI： 10.1016/s0378-4347(00)83928-6

Source DB:  PubMed          Journal:  J Chromatogr


× No keyword cloud information.
  11 in total

1.  Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.

Authors:  Peter H O'Donnell; Andrew S Artz; Samir D Undevia; Rish K Pai; Paula Del Cerro; Sarah Horowitz; Lucy A Godley; John Hart; Federico Innocenti; Richard A Larson; Olatoyosi M Odenike; Wendy Stock; Koen Van Besien
Journal:  Leuk Lymphoma       Date:  2010-10-04

Review 2.  The role of busulfan in bone marrow transplantation.

Authors:  M Hassan
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

3.  Gas-chromatographic analysis of busulfan for therapeutic drug monitoring.

Authors:  L Embree; R B Burns; J R Heggie; G L Phillips; D E Reece; J J Spinelli; D O Hartley; N J Hudon; J H Goldie
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Iron Overload Exacerbates Busulfan-Melphalan Toxicity Through a Pharmacodynamic Interaction in Mice.

Authors:  Jérôme Bouligand; Clémentine Richard; Dominique Valteau-Couanet; Cedric Orear; Lionel Mercier; Romain Kessari; Nicolas Simonnard; Fabienne Munier; Estelle Daudigeos-Dubus; Bassim Tou; Paule Opolon; Alain Deroussent; Angelo Paci; Gilles Vassal
Journal:  Pharm Res       Date:  2016-04-18       Impact factor: 4.200

5.  Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation.

Authors:  G Vassal; S Koscielny; D Challine; D Valteau-Couanet; I Boland; A Deroussent; J Lemerle; A Gouyette; O Hartmann
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

6.  Exposure equivalence between IV (0.8 mg/kg) and oral (1 mg/kg) busulfan in adult patients.

Authors:  F Léger; L Nguyen; C Puozzo
Journal:  Eur J Clin Pharmacol       Date:  2009-05-08       Impact factor: 2.953

7.  Hepsulfam distribution in blood, plasma and cerebrospinal fluid of baboons.

Authors:  M V Marshall; K D Carey; D D Von Hoff; J G Kuhn
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

8.  Pharmacokinetics of high-dose busulfan in children.

Authors:  G Vassal; A Gouyette; O Hartmann; J L Pico; J Lemerle
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

9.  Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations.

Authors:  I Boland; G Vassal; J Morizet; M J Terrier-Lacombe; D Valteau-Couanet; C Kalifa; O Hartmann; A Gouyette
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

10.  A rapid & sensitive liquid chromatography- tandem mass spectrometry method for the quantitation of busulfan levels in plasma & application for routine therapeutic monitoring in haematopoietic stem cell transplantation.

Authors:  Salamun Desire; Ezhil Pavai Mohanan; Biju George; Vikram Mathews; Mammen Chandy; Alok Srivastava; Poonkuzhali Balasubramanian
Journal:  Indian J Med Res       Date:  2013-04       Impact factor: 2.375
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.